[Skip to Content]
[Skip to Content Landing]
Views 401
Citations 0
Research Letter
September 11, 2017

Possible Insufficiency of Generic Price Competition to Contain Prices for Orally Administered Anticancer Therapies

Author Affiliations
  • 1Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill
  • 2Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
  • 3School of Medicine, University of North Carolina, Chapel Hill
  • 4Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, Chapel Hill
  • 5Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill
JAMA Intern Med. Published online September 11, 2017. doi:10.1001/jamainternmed.2017.2788

Generic price competition is viewed as an important way to contain prices and increase patient access to prescription medications.1,2 Following the introduction of generic options, substantial decreases have been observed in prices for infused anticancer therapies. However, it is unclear whether such declines will be observed for orally administered anticancer drugs.3 Capecitabine is one of the first high-priced orally administered anticancer drugs to lose patent protection in the United States, making it a useful case study for understanding how generic entry may affect orally administered anticancer drug prices.

First Page Preview View Large
First page PDF preview
First page PDF preview